GSK oncology comeback nears sixth approval as pipeline matures

GSK, which exited oncology a decade ago, is now close to securing approval for its sixth cancer drug, signaling a successful strategic pivot. The company's return to cancer R&D is yielding tangible regulatory milestones, though commercial uptake and competition remain uncertain. This marks a notable shift in GSK's portfolio focus and could impact its growth trajectory.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works